← All trials
NCT05578508
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Oct 13, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 0
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The Cleveland ClinicLead sponsor
- Case Western Reserve UniversityCollaborator
- The Cleveland ClinicOverall official - principal investigator
- The Cleveland ClinicReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.